CEBP Infection and Cancer: Biology, Therapeutics, and Prevention Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Semmler, A.
Right arrow Articles by Linnebank, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Semmler, A.
Right arrow Articles by Linnebank, M.
Cancer Epidemiology Biomarkers & Prevention Vol. 15, 2314-2316, November 2006
© 2006 American Association for Cancer Research

Short Communication

The Methionine Synthase Polymorphism c.2756A>G Alters Susceptibility to Glioblastoma Multiforme

Alexander Semmler1, Matthias Simon2, Susanna Moskau1 and Michael Linnebank1

Departments of 1 Neurology and 2 Neurosurgery, University Hospital Bonn, Bonn, Germany

Requests for reprints: Michael Linnebank, Department of Neurology, University Hospital Bonn, Sigmund-Freud-Straße, 25, 53105 Bonn, Germany. Phone: 49-228-287-5712; Fax: 49-228-287-5024. E-mail: Michael.Linnebank{at}ukb.uni-bonn.de

Genetic polymorphisms of methionine metabolism, in particular methionine synthase (MTR) c.2756A>G (D919G) and methylenetetrahydrofolate reductase (MTHFR) c.677C>T (A222V), have been associated with various human cancers. We investigated MTR c.2756A>G, MTHFR c.677C>T, and a third polymorphism, transcobalamin 2 c.776C>G (P259R), for a potential association with the formation of glioblastoma multiforme. The MTR c.2756G allele was significantly underrepresented among 328 glioblastoma multiforme patients of Caucasian origin when compared with 400 population controls [patients AA/AG/GG: 0.72/0.26/0.02 and controls AA/AG/GG: 0.57/0.38/0.05, degrees of freedom = 2; {chi}2 = 17.86 (Pearson); P < 0.001]. No association between glioblastoma multiforme and the two other polymorphisms was observed. (Cancer Epidemiol Biomarkers Prev 2006;15(11):2314–6)




This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
L. Bethke, E. Webb, A. Murray, M. Schoemaker, M. Feychting, S. Lonn, A. Ahlbom, B. Malmer, R. Henriksson, A. Auvinen, et al.
Functional Polymorphisms in Folate Metabolism Genes Influence the Risk of Meningioma and Glioma
Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1195 - 1202.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2006 by the American Association for Cancer Research.